Clinical Trial Update: A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG) [Phase 3]

View source ↗

Summary

Phase 3 open-label study of eculizumab in pediatric patients with refractory generalized myasthenia gravis completed; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myasthenia Gravis

Drugs mentioned

• Eculizumab (eculizumab)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Myasthenia Gravis, Myasthenia Gravis, Juvenile Form | Phase 3 | Status: COMPLETED | Results posted: 2022-08-25